Humoral immune system in inflammatory bowel disease: I. Complement levels

Area of Science:

• Immunology
• Gastroenterology
• Biochemistry

Background:

• Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, involve complex immune dysregulation.
• The complement system, a crucial part of innate immunity, plays a role in inflammation and host defense.
• Alterations in complement component levels may serve as biomarkers for disease activity in IBD.

Purpose of the Study:

• To investigate the serum levels of key complement components in patients with ulcerative colitis and Crohn's disease.
• To determine if complement pathway activation differs between the classical and alternative pathways in active IBD.
• To assess the correlation between complement levels and disease activity (active vs. remission).

Main Methods:

• Quantification of serum complement components: Clq, C4, C3, and Properdin factor B.
• Comparison of complement levels between patients with active IBD, IBD in remission, and healthy hospital controls.
• Analysis of complement component consumption patterns across different disease states.

Main Results:

• Elevated serum concentrations of C3, factor B, and to a lesser extent C4 were observed during active phases of ulcerative colitis and Crohn's disease.
• In patients with IBD in remission, complement component levels were comparable to those of hospital control subjects.
• No evidence suggested a preferential consumption of complement proteins from either the classical or alternative pathway, even in the presence of circulating immune complexes.

Conclusions:

• Serum levels of specific complement components (C3, factor B, C4) are elevated during active IBD, reflecting systemic inflammation.
• Complement component levels normalize during remission, suggesting they can serve as indicators of disease activity.
• The complement system's activation in IBD does not appear to preferentially involve either the classical or alternative pathway.